NewAmsterdam Pharma (NASDAQ:NAMS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating [Seeking Alpha]
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma (NASDAQ:NAMS) had its price target raised by analysts at Royal Bank Of Canada from $39.00 to $44.00. They now have an "outperform" rating on the stock.